Literature DB >> 6828758

Treatment of hepatic neoplasm through extrahepatic collaterals.

C S Soo, V P Chuang, S Wallace, C Charnsangavej, H Carrasco.   

Abstract

Twenty-nine patients with hepatic artery occlusion were treated with additional hepatic infusion or embolization through extrahepatic collaterals. Seventeen courses of hepatic infusion were performed in 13 patients through the inferior pancreaticoduodenal artery, left gastric artery, or right gastric artery. Twenty-five hepatic embolization procedures were performed in 16 patients through the right and left phrenic arteries, left and right gastric arteries, pancreaticoduodenal artery, gastroduodenal artery, or omentoepiploic artery. In one patient gastric ulcers developed following left gastric artery infusion. No complication related to the embolization procedure was observed in the embolization group. The extrahepatic collaterals are important alternative routes for continuous transcatheter management of hepatic neoplasms following hepatic artery occlusion.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6828758     DOI: 10.1148/radiology.147.1.6828758

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  15 in total

Review 1.  Vascular anatomy of the pancreas and clinical applications.

Authors:  K Ibukuro
Journal:  Int J Gastrointest Cancer       Date:  2001

2.  Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report.

Authors:  C C Case; K Wirfel; R Vassilopoulou-Sellin
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

3.  The role of surgery in the management of unusual complications of transcatheter arterial embolization for hepatocellular carcinoma.

Authors:  K S Jeng; H J Ching
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

4.  Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma.

Authors:  Dingxin Wang; Brian Jin; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Mary F Mulcahy; Laura M Kulik; Frank H Miller; Riad Salem; Debiao Li; Reed A Omary; Andrew C Larson
Journal:  J Magn Reson Imaging       Date:  2010-05       Impact factor: 4.813

5.  Blood supply characteristics of pedunculated hepatocellular carcinoma prior to and following transcatheter arterial chemoembolization treatment: An angiographic demonstration.

Authors:  Dexiao Huang; Yong Chen; Qingle Zeng; Jianbo Zhao; Xizhong Wu; Renhua Wu; Yanhao Li
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

6.  Internal mammary artery embolization for hepatic tumors.

Authors:  S E Macaulay; D M Coldwell
Journal:  Cardiovasc Intervent Radiol       Date:  1995 Jan-Feb       Impact factor: 2.740

7.  Four-dimensional transcatheter intraarterial perfusion MR imaging for monitoring chemoembolization of hepatocellular carcinoma: preliminary results.

Authors:  Ron C Gaba; Dingxin Wang; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Laura M Kulik; Mary F Mulcahy; Andrew C Larson; Riad Salem; Reed A Omary
Journal:  J Vasc Interv Radiol       Date:  2008-09-25       Impact factor: 3.464

8.  Celiac axis stenosis: incidence and etiologies in asymptomatic individuals.

Authors:  C M Park; J W Chung; H B Kim; S J Shin; J H Park
Journal:  Korean J Radiol       Date:  2001 Jan-Mar       Impact factor: 3.500

9.  Repeat operation for nodular recurrent hepatocellular carcinoma within the cirrhotic liver remnant: a comparison with transcatheter arterial chemoembolization.

Authors:  K S Jeng; F S Yang; H J Chiang; I Ohta
Journal:  World J Surg       Date:  1992 Nov-Dec       Impact factor: 3.352

10.  The usefulness of cone-beam computed tomography during chemoembolization of hepatocellular carcinomas fed exclusively by the cystic artery.

Authors:  Mitsuhiro Kinoshita; Katsuya Takechi; Seiji Iwamoto; Shoichiro Takao; Ryozo Shirono; Masafumi Harada
Journal:  Jpn J Radiol       Date:  2016-09-21       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.